Express News | Guggenheim Reiterates Buy on UroGen Pharmato Buy
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $55
$URGN Stock Is up 7% Today. Here's What We See in Our Data.
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as Trade Tensions Persist
Top Premarket Gainers
UroGen Pharma Price Target Maintained With a $25.00/Share by D. Boral Capital
UroGen Pharma Reports Nearly 4-Year Response for Urothelial Cancer Therapy -- Shares Up Pre-Bell
Reported Sunday, UroGen Highlights Nearly Four-Year Duration Of Response In OLYMPUS Long-Term Follow-Up Study Of JELMYTO
Reported Saturday, UroGen Pharma's UGN-301 Phase 1 Trial Shows Sustained Bladder Exposure And No Dose-Limiting Toxicities In Non-Muscle Invasive Bladder Cancer
UroGen Pharma Announces Encouraging Results From a Phase 1 Dose-Escalation Study Evaluating...
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% From the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40
UroGen Pharma Is Maintained at Neutral by Goldman Sachs
This H.B. Fuller Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Scotiabank Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $23
Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Cuts Target Price to $16
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Express News | Urogen Pharma Ltd : Scotiabank Initiates Coverage With Sector Outperform Rating; Target Price $23
Express News | UroGen To Present At American Urological Association 2025 Annual Meeting Apr. 26 and 27